1. Home
  2. PRTC vs PUBM Comparison

PRTC vs PUBM Comparison

Compare PRTC & PUBM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PRTC
  • PUBM
  • Stock Information
  • Founded
  • PRTC 2015
  • PUBM 2006
  • Country
  • PRTC United States
  • PUBM United States
  • Employees
  • PRTC N/A
  • PUBM N/A
  • Industry
  • PRTC Biotechnology: Pharmaceutical Preparations
  • PUBM Computer Software: Prepackaged Software
  • Sector
  • PRTC Health Care
  • PUBM Technology
  • Exchange
  • PRTC Nasdaq
  • PUBM Nasdaq
  • Market Cap
  • PRTC 388.6M
  • PUBM 382.7M
  • IPO Year
  • PRTC N/A
  • PUBM 2020
  • Fundamental
  • Price
  • PRTC $15.39
  • PUBM $8.15
  • Analyst Decision
  • PRTC Buy
  • PUBM Buy
  • Analyst Count
  • PRTC 1
  • PUBM 11
  • Target Price
  • PRTC $45.00
  • PUBM $18.05
  • AVG Volume (30 Days)
  • PRTC 5.0K
  • PUBM 600.8K
  • Earning Date
  • PRTC 08-28-2025
  • PUBM 11-11-2025
  • Dividend Yield
  • PRTC N/A
  • PUBM N/A
  • EPS Growth
  • PRTC N/A
  • PUBM N/A
  • EPS
  • PRTC 0.20
  • PUBM N/A
  • Revenue
  • PRTC $6,391,000.00
  • PUBM $292,208,000.00
  • Revenue This Year
  • PRTC N/A
  • PUBM N/A
  • Revenue Next Year
  • PRTC N/A
  • PUBM $1.70
  • P/E Ratio
  • PRTC $7.29
  • PUBM N/A
  • Revenue Growth
  • PRTC 1265.60
  • PUBM 3.53
  • 52 Week Low
  • PRTC $13.30
  • PUBM $7.01
  • 52 Week High
  • PRTC $24.99
  • PUBM $17.74
  • Technical
  • Relative Strength Index (RSI)
  • PRTC 34.46
  • PUBM 38.11
  • Support Level
  • PRTC $15.75
  • PUBM $8.04
  • Resistance Level
  • PRTC $16.75
  • PUBM $8.54
  • Average True Range (ATR)
  • PRTC 0.62
  • PUBM 0.29
  • MACD
  • PRTC -0.14
  • PUBM 0.10
  • Stochastic Oscillator
  • PRTC 0.00
  • PUBM 14.29

About PRTC PureTech Health plc

PureTech Health PLC, together with its subsidiaries, is a clinical-stage biopharma company developing medicines to modulate the adaptive human system. The company is focused on developing and commercializing differentiated medicines for devastating diseases, including inflammatory, immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological and neuropsychological disorders, among others. Its drug development pipeline consists of Deupirfenidone (LYT-100), for the potential treatment of idiopathic pulmonary fibrosis (IPF), LYT-200, SPT-300, an oral drug for depressive disorder, SPT-320, and others. The company's operating segments include Parent Companies & Other, which derives key revenue, Wholly-Owned Programs, and Controlled Founded Entities.

About PUBM PubMatic Inc.

PubMatic Inc is a supply-side platform provider in the digital advertising technology market. These platforms help publishers, which supply digital ad inventory, manage their inventory, selling a high percentage of their inventory (increase the ad fill rate) and maximizing revenue per ad sold (optimize yield). The company generates revenue mainly by taking a piece of the ad sales that it enables. Buyers on the platform include intermediary buyers, such as demand-side platforms, or advertisers and ad agencies directly. Geographically, the company generates the majority of its revenue from the United States, followed by EMEA and APAC.

Share on Social Networks: